FluoGuide develops surgical solutions that are expected to reduce suffering for the patient and increase the likelihood of cure as well as reducing costs for the health care system.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North


FluoGuide was incorporated in 2018 based on decades of groundbreaking research on imaging, cancer and uPAR.

FluoGuide was founded by Andreas Kjaer, who is an MD, PhD, DMSc and MBA and holds a position as professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark. Professor Kjaer’s research has been focused on molecular imaging with PET, PET/MRI and optical imaging as well as targeted radionuclide therapies (theranostics) in cancer. Before the founding of FluoGuide, Kjaer and his research group has made extensive research within the field. In 2017 Professor Andreas Kjaer as project leader received the prestigious Grand Solutions grant from Innovation Fund Denmark for the FluoGuide project. The project has the objective to expand the pipeline for fluorophore based products.